Antigen-specific immunoadsorption of anti-acetylcholine receptor antibodies from sera of patients with myastenia gravis

5Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: The binding of anti-acetylcholine receptor antibodies (AChRAb) to the main immunogenic region (MIR) of AChR α-subunit in the neuromuscular junction is the major pathogenesis of myasthenia gravis (MG). Methods: A synthetic peptide of 10 amino acids corresponding to the MIR of human AChR was coupled with cellulose beads to make an antigen-specific immunoadsorbent (hMIR10-CB). Results: The hMIR10-CB could remove AChRAb in MG sera by 40.3±2.3%, compared to a tryptophan nonspecific adsorbent Trp-CB by only 22.4±1.5% as determined in ELISA, and also showed good blood compatibility for blood cells, plasma ions and plasma proteins as checked in whole blood perfusion in rabbits. Conclusions: The antigen-specific immunoadsorbent hMIR10-CB can serve as a potential candidate in the immunoadsorption treatment of MG. © Informa UK Ltd.

Cite

CITATION STYLE

APA

Sun, C., Meng, F., Li, Y., Jin, Q., Li, H., & Li, F. (2010). Antigen-specific immunoadsorption of anti-acetylcholine receptor antibodies from sera of patients with myastenia gravis. Artificial Cells, Blood Substitutes, and Biotechnology, 38(2), 99–102. https://doi.org/10.3109/10731191003634778

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free